| Politician | Action | Description | Traded |
|---|---|---|---|
| Sell | Oramed Pharmaceuticals Inc. | Jan 10, 2025 | |
| Sell | Oramed Pharmaceuticals Inc. | Jan 14, 2022 | |
| Sell | Oramed Pharmaceuticals Inc. | Oct 1, 2021 | |
| Buy | Oramed Pharmaceuticals Inc. | Apr 23, 2021 |
This page tracks congressional stock trading activity in Oramed Pharmaceuticals Inc. (ORMP) in the Healthcare sector. Disclosed Capitol has indexed 4 disclosed congressional trades involving ORMP. Every trade is sourced from official STOCK Act financial disclosure filings — the same primary records the Senate and House are required to publish. The full trade list with politician names, transaction types, amount ranges, and disclosure dates is below, alongside cross-references to any related lobbying activity, federal contracts, and committee assignments.
As of February 2025 — Disclosed Capitol has tracked 4 disclosed congressional trades in Oramed Pharmaceuticals Inc. (ORMP) — 3 sells with no recorded buys — led by Andrew Garbarino (R).
| Date | Politician | Party | Action | Amount |
|---|---|---|---|---|
| Jan 10, 2025 | Brad Knott | R | Sale | $15,001 - $50,000 |
| Jan 14, 2022 | Andrew Garbarino | R | Sale | $1,001 - $15,000 |
| Oct 1, 2021 | Andrew Garbarino | R | Sale | $1,001 - $15,000 |
| Apr 23, 2021 | Andrew Garbarino | R | Buy | $1,001 - $15,000 |
Across the 4 disclosed congressional trades in Oramed Pharmaceuticals Inc. (ORMP), members of Congress have reported 0 buys and 3 sells. The average 30-day alpha vs. the S&P 500 is -0.11%.
For fiscal year 2025, Oramed Pharmaceuticals Inc. reported revenue of $2.0M and net income of $64.0M, per SEC filings.
Most recent reported quarter: Q2 FY2026 — revenue $0, net income $13.3M.
Figures come from SEC financial statement filings. The full annual and quarterly statement history is in the Financials tab above.